Skip to main content
. 2015 Jan 1;25(1):71–77. doi: 10.1089/thy.2014.0123

FIG. 3.

FIG. 3.

Partial response in a BRAFV600E-mutant papillary thyroid cancer treated with dabrafenib. This patient achieved a 38% decrease in tumor size and received treatment for 12 months before progressing. (A) Baseline. (B) After 9 weeks of treatment. (C) After 39 weeks of treatment.